Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 9/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | CMA1 | P23946 | 3/20 | 0.53 |
| ▸ | ACP3 | P15309 | 2/20 | 0.53 |
| ▸ | MASP2 | O00187 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 6/20 | 0.48 |
| ▸ | CNR2 | P34972 | 5/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200589 | 0.99 | NPC1 (0.56) | CTSGNPC1CMA1ACP3MASP2 | |
| SCHEMBL4189774 | 0.89 | CTSG (0.52) | CTSGNPC1CMA1ACP3MASP2 | |
| SCHEMBL1614758 | 0.88 | CTSG (0.56) | CTSGNPC1CMA1ACP3MASP2 | |
| SCHEMBL31211679 | 0.86 | CTSG (0.68) | CTSGNPC1CMA1ACP3MASP2 | |
| SCHEMBL1613656 | 0.86 | CTSG (0.68) | CTSGNPC1CMA1ACP3MASP2 | |
| SCHEMBL6073103 | 0.84 | NPC1 (0.53) | CTSGNPC1CMA1ACP3CNR1 | |
| SCHEMBL1614368 | 0.83 | CTSG (0.63) | CTSGNPC1CMA1ACP3MASP2 | |
| SCHEMBL1614713 | 0.82 | CTSG (0.62) | CTSGNPC1CMA1ACP3MASP2 | |
| SCHEMBL8350432 | 0.80 | CTSG (0.68) | CTSGCMA1ACP3MASP2 | |
| SCHEMBL1613511 | 0.79 | CTSG (0.51) | CTSGCMA1ACP3MASP2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247599-B2 | Phosphonic acid compounds as inhibitors of serine proteases | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-08-21 | — | — | US | claimed |
| US-20090118235-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | GRECO MICHAEL N | 2009-05-07 | — | — | US | claimed |
| EP-1438316-B1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | ORTHO MCNEIL PHARM INC (US) | 2006-06-21 | — | — | EP | claimed |
| EP-1438316-A1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-07-21 | — | — | EP | claimed |
| US-20040082544-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | claimed |
| US-20030195172-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | GRECO MICHAEL N (US) | 2003-10-16 | — | — | US | claimed |
| WO-2003035654-A1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-05-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082544-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | HPN, PRSS1, SERPINB1 | CTSG 251/4885NPC1 2609/4885CMA1 137/4885 |
| US-20030195172-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | HPN, PRSS1, SERPINB1 | CTSG 251/4885NPC1 2609/4885CMA1 137/4885 |
| US-20090118235-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | HPN, PRSS1, SERPINB1 | CTSG 251/4885NPC1 2609/4885CMA1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.